Artificial intelligence has finally moved from pharmaceutical press releases to patient bodies. A handful of drugs designed entirely by AI are now in human clinical trials, with at least one showing positive results in peer-reviewed studies. Over the next twelve months, pivotal Phase III trials will test whether a decade of AI drug discovery promises can actually work in real patients .

What Makes This Moment Different From Previous AI Hype?

The difference between today and previous AI announcements in healthcare is concrete and measurable. These are not drugs optimized or screened using AI as a supporting tool. They are drugs conceived and built by AI from the ground up, starting with identifying the disease target itself. Rentosertib, developed by Insilico Medicine, holds a specific distinction: it is the first drug in which both the disease target and the molecular compound were discovered using generative AI .

Rentosertib targets idiopathic pulmonary fibrosis (IPF), a progressive lung condition that kills most patients within two to five years of diagnosis. Existing approved therapies can slow disease progression, but none reverse it. Insilico's generative AI platform, called Pharma.AI, identified a novel disease target called TNIK, a protein kinase that drives fibrosis pathways, then designed a small molecule to inhibit it. The entire preclinical development program, from hypothesis and target discovery through to drug candidate generation, took just under 18 months at a budget of around $2.6 million .

By pharmaceutical standards, where a single compound can take years and tens of millions of dollars to reach preclinical candidacy, that timeline was remarkable. However, the drug still had to navigate the same Phase 0, Phase I, and Phase II clinical trials that any candidate must clear. There are no AI shortcuts in clinical testing.

What Do the Early Clinical Results Actually Show?

In November 2024, Insilico announced positive topline results from the Phase IIa trial, a randomized, double-blind, placebo-controlled study enrolling 71 patients with IPF across 21 sites in China. At the highest dose of 60 milligrams once daily, patients showed a mean improvement of 98.4 milliliters in forced vital capacity (FVC) from baseline. The placebo group, by contrast, showed a mean decline of 62.3 milliliters. The drug was well-tolerated across all dosing groups .

In June 2025, Insilico published the industry's first proof-of-concept clinical validation of AI-driven drug discovery in Nature Medicine. The company is now in discussions with regulatory authorities about a Phase IIb pivotal trial, while a separate Phase IIa trial in U.S. patients is actively enrolling. That published result is the most significant milestone this field has produced, though researchers are careful to note it is a starting point rather than a finish line .

Rentosertib is the furthest along, but it is far from alone. As of early 2026, over 173 AI-discovered drug programs are in clinical development, with 15 to 20 expected to enter pivotal trials during the year .

How to Understand the AI Drug Pipeline at a Glance

• Phase I Programs: Approximately 94 AI-discovered drugs are in early human safety testing, where researchers determine if a compound is safe enough to test in larger groups.
• Phase II Programs: Approximately 56 drugs are in mid-stage trials, where researchers begin testing whether the drug actually works for its intended disease.
• Phase III Programs: Approximately 15 drugs are in large-scale pivotal trials, the final hurdle before regulatory approval, where success or failure will determine whether AI can truly change drug development.

The Phase III number is the one the industry is watching most closely. This is where the pharmaceutical industry's persistent overall failure rate is driven heavily by late-stage failures, where drugs that worked in smaller trials turn out not to work in larger and more diverse patient populations .

Several companies are advancing AI-designed molecules toward this critical milestone. The merged entity of Recursion and Exscientia, completed in mid-2025, now has more than 10 clinical and preclinical programs in its internal pipeline and over $20 billion in potential milestone payments from partners. Key 2026 pipeline updates include a Phase II readout for REC-394 in C. difficile infection and Phase I data for REC-1245, an RBM39 degrader in oncology .

Schrödinger uses a physics-based AI approach rather than purely data-driven generative models. Its compound zasocitinib, developed through a partnership with Nimbus Therapeutics and later acquired by Takeda, is now in Phase III. Takeda reported in December 2025 that the AI-designed molecule eased the severity of plaque psoriasis in two late-stage trials, positioning zasocitinib as a leading candidate for what may become the first FDA approval of an AI-discovered drug .

The Google DeepMind spinout Isomorphic Labs has not yet advanced compounds into clinical trials, but its technological position is formidable. In January 2026, Isomorphic Labs announced a research collaboration with Johnson and Johnson, leveraging its IsoDDE drug design engine for multi-modality drug discovery across small molecules and biologics. The company's platform reportedly more than doubles AlphaFold 3's accuracy on challenging protein-ligand structure prediction benchmarks, which matters directly for identifying viable drug targets and predicting how tightly a molecule will bind .

Where Is AI Actually Winning in Drug Development?

The emerging clinical data on AI-discovered drugs deserves careful interpretation rather than uncritical celebration or easy dismissal. Phase I performance is striking. AI-discovered molecules are achieving success rates of 80 to 90 percent in early human trials, significantly higher than the roughly 52 percent historical average for traditional methods. This reflects something real: AI platforms are substantially better at predicting which compounds will be safe and well-tolerated before they ever reach clinical testing. Better early filtering means fewer surprises when humans are first dosed .

Phase II performance is encouraging but still limited by sample size. AI-discovered drugs are showing approximately 65 to 75 percent success rates compared to 30 to 45 percent for traditional approaches. However, Phase III is where the real test lies. AI has not yet demonstrated that it can materially change the odds of success in large-scale trials with diverse patient populations .

The honest framing is this: AI has made the early part of drug development faster and cheaper. Whether it can make the clinical part more successful is the question 2026 is beginning to answer.

What Are the Real Failures That Nobody Talks About?

These failures are a useful corrective to any narrative that treats AI drug discovery as a guaranteed improvement on traditional methods. In May 2025, Recursion discontinued its lead AI-discovered candidate REC-994 for cerebral cavernous malformation after long-term data did not confirm earlier efficacy trends. Earlier, in 2023, AI-designed compounds missed endpoints in trials for atopic dermatitis, schizophrenia, and cancer. Failure rates in clinical medicine are stubborn, and AI has not yet proven it can tame them .

During the rentosertib program, Insilico's Chemistry42 platform generated 78,000 virtual TNIK inhibitors, filtered these through multi-objective optimization, and synthesized the 60 top-ranked compounds. The hit rate was 16.7 percent, demonstrating that even with AI's ability to screen millions of candidates, the actual success rate in identifying viable compounds remains modest .

The term "AI drug discovery" covers a range of meaningfully different technical approaches, and the distinctions matter for understanding what each platform can and cannot do. Generative AI, the approach Insilico Medicine uses and the most widely discussed in public coverage, learns the relationship between molecular structure and biological activity across millions of known compounds, then designs new candidates optimized for potency, selectivity, and favorable pharmacokinetic properties .

What happens in 2026 will determine whether the past decade of investment and hype translates into a genuine transformation of pharmaceutical development, or whether AI's role remains limited to accelerating the early stages of a process whose fundamental challenges remain unsolved.

" }